![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, December 08, 2017 11:15:30 AM
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136609956
Your Hyperbolic words in response to biodoc:
“But what you write really has no practical application for ipix. Primary endpoint failure would be devastating. There’d be no second chances.”
So that IPIX’s main Secondary outcome (Duration) is what most other Rx are using as their Primary — not Incidence, like us — isn’t relevant???
Other Rx in fact are saying Duration **is good enough** to get approved and this with Regulatory input (eg SGNX Ph 3 trial design)
Your logic: Does. Not. Compute.
As to B-OM, I do expect a Reduction in Incidence (Primary) vs placebo and Reduction in Duration (Secondary)
how great the spread need be in Primary?
Anything over 10pt imo a success.
Anything over 20pt imo Big Success.
Anything over 30pt imo HUGE.
Again there is no approved OM treatment out there other than KEPIVANCE, with limited label, recently pulled from Europe. OM doubles cost of care and results in 20% dying prematurely from what I recall reading.
So enough w the dire language — “failure” “devastating” “no second chances”
B OM has BTD potential and the FDA and any Rx Partner will see that if Topline delivers a successful trial.
Again our Secondary - Reduction in Duration - is other Rxs Primary... on its own, RID might elicit approval regardless of RII, highest bar
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM